Eli Lilly and Company's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made and spent in the first half of 2026, helping investors track if the business is growing.
Officially shared financial performance for Q2 2026 with investors, explaining if Mounjaro and Zepbound sales are growing.
Shows Eli Lilly has multiple bonds outstanding, meaning investors can lend money to the company at fixed interest rates.
Gives Eli Lilly permission to sell new stock or bonds anytime, letting them raise cash when needed for growth.
Stock owners voted against changing board structure; shows when big governance changes fail, the company keeps its current system.
Gives Eli Lilly permission to sell new stock or bonds anytime, letting them raise cash when needed for growth.
Shows how much money the company made and spent in early 2026, helping investors track quarterly business performance.
Stocky reads Eli Lilly and Company's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Eli Lilly and Company's most recent tracked filing was a 10-Q on 5 Aug 2026: Second quarter 2026 financial results filed with SEC.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.